Abstract
The generation of genetically engineered mouse models (GEMMs) that mimic breast cancer in humans provides new tools to investigate mechanisms of drug resistance in vivo. The advantages are manifold: inbred mice do not have the genomic heterogeneity seen in patients; mammary tumors are superficial and therefore easily accessible for measurement and sampling pre- and posttreatment; tumors can be transplanted orthotopically into syngeneic, immunocompetent animals; and tumor cells can be modified in vitro (e.g., gene overexpression, shRNA knockdown, insertional mutagenesis) prior to transplantation. Here, we provide an overview with experimental details of various approaches to study mechanisms of drug resistance in GEMMs for breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53:615–627
Borst P, Oude Elferink R (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537–592
Fojo T, Bates S (2003) Strategies for reversing drug resistance. Oncogene 22:7512–7523
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234
Fojo T (2007) Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat 10:59–67
Lee S, Schmitt CA (2003) Chemotherapy response and resistance. Curr Opin Genet Dev 13:90–96
Schmitt CA (2003) Senescence, apoptosis and therapy – cutting the lifelines of cancer. Nat Rev Cancer 3:286–295
Shabbits JA, Hu Y, Mayer LD (2003) Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2:805–813
Voorzanger-Rousselot N, Alberti L, Blay JY (2006) CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer 6:75
Debatin KM (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53:153–159
Sharpless NE, DePinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754
Rottenberg S, Jonkers J (2008) Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat 11:51–60
Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598
Kuperwasser C, Chavarria T, Wu M et al (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101:4966–4971
Marangoni E, Vincent-Salomon A, Auger N et al (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13:3989–3998
Van Dyke T, Jacks T (2002) Cancer modeling in the modern era: progress and challenges. Cell 108:135–144
Jonkers J, Berns A (2002) Conditional mouse models of sporadic cancer. Nat Rev Cancer 2:251–265
Jonkers J, Meuwissen R, van der Gulden H et al (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29:418–425
Derksen PW, Liu X, Saridin F et al (2006) Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10:437–449
Liu X, Holstege H, van der Gulden H et al (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with pathologic and molecular features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104:12111–12116
Rottenberg S, Nygren AOH, Pajic M et al (2007) Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 104:12117–12122
Rottenberg S, Jaspers JE, Kersbergen A et al (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105:17079–17084
Varticovski L, Hollingshead MG, Robles AI et al (2007) Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 13:2168–2177
Stingl J, Eirew P, Ricketson I et al (2006) Purification and unique properties of mammary epithelial stem cells. Nature 439:993–997
de Visser KE (2008) Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? Cancer Immunol Immunother 57:1531–1539
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603
Micke P, Ostman A (2005) Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9:1217–1233
Acknowledgments
Our work is supported by grants of the Dutch Cancer Society (2006-3566 to Piet Borst, S.R. and J.J.; 2007-3772 to J.J., S.R. and Jan H.M. Schellens) and the European Union (FP6 Integrated Project 037665-CHEMORES to Piet Borst and S. R.). We thank Piet Borst for critical reading of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Rottenberg, S., Pajic, M., Jonkers, J. (2010). Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer. In: Zhou, J. (eds) Multi-Drug Resistance in Cancer. Methods in Molecular Biology, vol 596. Humana Press. https://doi.org/10.1007/978-1-60761-416-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-60761-416-6_3
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-415-9
Online ISBN: 978-1-60761-416-6
eBook Packages: Springer Protocols